209960-91-8

Basic information

• Product Name: 2-methoxy-4-morpholinoaniline
• Synonyms: 2-methoxy-4-morpholinoaniline;2-methoxy-4-morpholinoaniline dihydrochloride;2-Methoxy-4-morpholin-4-yl-phenylamine;2-methoxy-4-(4-morpholinyl)Benzenamine;2-Methoxy-4-(morpholin-4-yl)aniline;2-Methoxy-4-morpholinobenzenamine
• CAS NO: 209960-91-8
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.259
• Mol File: 209960-91-8.mol
• Article Data: 22

Chemical Properties

• Melting Point: 78-80°
• Boiling Point: 408.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.163±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.30±0.40(Predicted)
• CAS DataBase Reference: 2-methoxy-4-morpholinoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxy-4-morpholinoaniline(209960-91-8)
• EPA Substance Registry System: 2-methoxy-4-morpholinoaniline(209960-91-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 209960-91-8(Hazardous Substances Data)

Usage

General Description

2-methoxy-4-morpholinoaniline, also known as Memantine, is a chemical compound with the molecular formula C12H17N2O. It is a pharmaceutical drug used to treat moderate to severe Alzheimer's disease and dementia. Memantine works by blocking the activity of certain receptors in the brain, specifically the N-methyl-D-aspartate (NMDA) receptors, which are involved in learning and memory. This helps to regulate the activity of glutamate, a neurotransmitter that is believed to play a role in Alzheimer's disease. Memantine is available in various forms, including oral tablets, oral solutions, and extended-release capsules, and is typically taken once or twice daily under the supervision of a healthcare professional. It has been shown to improve cognitive function and slow the progression of Alzheimer's disease in some patients. However, like any medication, Memantine may cause side effects, such as dizziness, headache, confusion, and constipation, and should only be used as directed by a doctor.

Upstream product

• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 
• 175135-19-0 AMA₅₆ 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 6950-88-5 4-(3-methoxy-4-nitro-phenyl)morpholine 

Downstream Products

• 1372263-46-1 N₄-benzyl-N₂-(2-methoxy-4-morpholinophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
• 1372262-89-9 N-(2-methoxy-4-morpholinophenyl)-4-(methylsulfonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1372262-90-2 N-ethyl-N-(3-((2-(2-methoxy-4-morpholinophenylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide 
• 1372262-84-4 N-ethyl-N-{3-[( {2-[(2-methoxy-4-morpholin-4-ylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)methyl]pyridin-2-yl}methanesulfonamide 
• 1372262-88-8 N-(2-methoxy-4-morpholinophenyl)-4-(methylthio)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 

Relevant articles and documents

COMPOUNDS AND THEIR USES AS MIF INHIBITORS

The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the i

Discovery and structure ? activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Internal tandem duplications of FLT3 (FLT3-ITD) occur in approximately 25% of all acute myeloid leukemia (AML) cases and confer a poor prognosis. Optimization of the screening hit 1 from our in-house compound library led to the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives as potent and selective FLT3-ITD inhibitors. Compounds 17 and 19 displayed potent FLT3-ITD activities both with IC50 values of 0.4 nM and excellent antiproliferative activities against AML cell lines. Especially, compounds 17 and 19 inhibited the quizartinib resistance- conferring mutations, FLT3D835Y, both with IC50 values of 0.3 nM. Moreover, western blot analysis indicated that compounds 17 and 19 potently inhibited the phosphorylation of FLT3 and attenuated downstream signaling in AML cells. These results indicated that pyrazolo[1,5-a]pyrimidine derivatives could be promising FLT3-ITD inhibitors for the treatment AML.

Design, synthesis and biological evaluation of novel pteridinone derivatives as potent dual inhibitors of PLK1 and BRD4

To develop novel simultaneous inhibition of PLK1 and BRD4 bromodomain by a single molecule, three series of novel pteridinone derivatives were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against A549, HCT116, PC-3 and MCF-7 cell lines. The most promising compound III4 showed high antiproliferative effects on four cell lines with IC50 values of 1.27 μM, 1.36 μM, 3.85 μM and 4.06 μM, respectively. The enzymatic assay identified III4 as a potent PLK1 and BRD4 dual inhibitor with % inhibition values of 96.6 and 59.1, respectively. Furthermore, to clarify the anticancer mechanism of the target compounds, explorations in the bioactivity were conducted. The results showed that compound III4 obviously inhibited the proliferation of HCT-116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of cancer cells, suppressed the migration of tumor cells, and arrested the S phase of HCT116 cells.